Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant is expected to have a positive outlook due to the growth in R&D expenses for the development of IMVT-1402, which has shown promising results in reducing levels of pathogenic IgG antibodies in autoimmune diseases. The decline in G&A expenses also indicates efficient cost management. With a strong cash position of $994.5M, Immunovant is well-positioned to continue their operations and support the potential launch of IMVT-1402 in GD, further solidifying its future growth potential.

Bears say

Immunovant is facing significant competition and potential risk of clinical failure as Janssen's trial with a similar drug failed to show added efficacy. Despite a differentiated trial design and patient population, the potential for significant sales in the Difficult-to-Treat RA market may not be fully reflected in the stock's current valuation. Additionally, the company's financials may be impacted by the overenrollment in their Phase 2b study, and the potential for a low placebo rate may obscure the true efficacy of the drug.

Immunovant Inc (IMVT) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 9 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.